fda tirzepatide compound approval Judge says compounding pharmacies must stop making copies of Zepbound, Mounjaro The FDA has strictly clarified

The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)

The next step was to investigate if these improvements in half-lives could be transposed in vivo

Tell your healthcare professional if you experience new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior, the FDA wrote

Lifestyle effects on aging and CVD: A spotlight on the nutrient-sensing network

Wegovy (semaglutide) The STEP UP trial followed 1,407 adults with obesity over 72 weeks

262,263 Additionally, substituting dietary SFAs with monounsaturated fatty acids improves nerve function in HFD mice without significantly altering plasma metabolic profiles, suggesting that dietary fats influence neuropathy development